[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634654":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":43,"collaborators":45,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Société Algérienne de Formation et Recherche en Oncologie","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"Patients treated with a pertuzumab biosimilar in the neoadjuvant setting for HER2-positive breast cancer.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2","Patients treated with a pertuzumab biosimilar as first-line therapy in the metastatic setting for HER2-positive metastatic breast cancer.",[16,34],{"facility":17,"status":18,"city":19,"state":10,"zip":10,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"CAC BLIDA, Algiers, Algeria 16000","RECRUITING","Algiers","Algeria","DZ",{"type":23,"coordinates":24},"Point",[25,26],3.08746,36.73225,{"lat":26,"lon":25},[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"BOUNEDJAR Adda, Professor","CONTACT","+213 25 20 90 72","contact@esclinicalresearch.com",{"facility":35,"status":18,"city":19,"state":10,"zip":10,"country":20,"countryCode":21,"cosmosGeoPoint":36,"geoPoint":38,"contacts":39},"CHU Béni Messous, Algiers, Algeria 16000",{"type":23,"coordinates":37},[25,26],{"lat":26,"lon":25},[40],{"name":41,"role":31,"phone":42,"phoneExt":10,"email":33},"Oukkal Mohammed, Professor","+213 219 311 90",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46,49],{"name":47,"class":48},"ES Clinical Research","UNKNOWN",{"name":50,"class":48},"AlgenPharm","100634654","real-world-bicohort-observational-study-of-a-pertuzumab-biosimilar-in-the-treatment-of-breast-cancer-in-the-neoadjuvant-setting-and-in-first-line-metastatic-disease-100634654",false,"NCT07542496","Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease","PERTUREAL","Inclusion Criteria:\n\n* Age ≥ 19 years at the time of inclusion;\n* Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH\u002FCISH\u002FSISH);\n* Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications;\n* Treatment prescribed as part of routine clinical care (outside of a clinical trial);\n* Patient informed and having provided written informed consent.\n\nExclusion Criteria:\n\n* Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.);\n* Treatment administered as part of an interventional clinical trial;\n* History of severe allergy or known contraindication to pertuzumab;\n* Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.","FEMALE","19 Years",{"count":61,"type":62},1000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.",[66,67],"Breast Cancer","Her 2 Positive Breast Cancer",[69,70,20,71,72,66,73,74,75,76,77,78,79,80,81],"Algerian Study","Real-world data","Biosimilar","Pertuzumab","Cancer","Breast cancer in Algerian patients","HER2-Positive Breast Cancer","Neoadjuvant Therapy","Anti-HER2 Therapy","Cohort Study","Non-Interventional Study","HER2-Targeted Therapy","Observational Study","2026-04-14",{"date":84,"type":85},"2026-04-21","ACTUAL",{"date":87,"type":85},"2026-01-15",{"date":89,"type":62},"2027-01-15",{"name":5,"class":6},2]